MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided here...

Full description

Saved in:
Bibliographic Details
Main Authors ROCCHETTI, FRANCESCA, D'ALESSIO, JOSEPH ANTHONY, MCNEILL, ERIC, SIPOS, SZABOLCS, PROSZENYAK, AGNES, MARAGNO, ANA LETICIA, DELACOUR, LEA, STARCK, JEROME, PALERMO, MARK G, COLLAND, FREDERIC, GENESTE, OLIVIER, YU, BING, ZHANG, QIANG, CHANRION, MAIA, NAKAJIMA, KATSUMASA, BURGER, MATTHEW T, KOSTOVA, VESELA, CSEKEI, MARTON, HENLIN, JEAN-MICHEL, CHEN, ZHUOLIANG, DESOS, PATRICE, KOTSCHY, ANDRAS
Format Patent
LanguageEnglish
French
Published 26.11.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed. L'invention concerne des conjugués anticorps-médicament qui se lient à des cibles en oncologie humaine. Ces conjugués anticorps-médicament comprennent une fraction médicamenteuse inhibitrice de Mcl-1. L'invention concerne en outre des procédés et des compositions destinés à être utilisés dans le traitement de cancers par l'administration des conjugués anticorps-médicament décrits. L'invention concerne également des conjugués lieur-médicament comprenant une fraction médicamenteuse inhibitrice de Mcl-1 et des procédés de préparation de ceux-ci.
Bibliography:Application Number: CA20203138058